Ingredients
Cambrex is accelerating API capacity expansion across the US and Europe, advancing a $120m Iowa project and a $30m Milan upgrade as it builds scale in complex chemistries, peptides and high-potency manufacturing amid rising reshoring demand.
Polpharma has opened an India office to work more closely with API suppliers, improve oversight and strengthen supply chain resilience, marking an early strategic move under new CEO Sebastian Szymanek.
As India implements minimum import prices for certain antibiotics and key starting materials, Sandoz's Simon Goeller speaks to Generics Bulletin about the potential for Chinese suppliers to dominate the world market and weaponize supply.
As India implements minimum import prices for certain antibiotics and key starting materials, Sandoz's Simon Goeller speaks to Generics Bulletin about the potential for Chinese suppliers to dominate the world market and weaponize supply.
Phlow and Fresenius Kabi are partnering in the US to establish a fully domestic manufacturing pathway for epinephrine injection, with launch targeted for 2027 pending approvals. The collaboration is aimed at addressing the current lack of a US-based API producer.
A joint pilot between Phlow and AI biotech Enveda suggests high-quality data and deep learning could cut Phlow’s active pharmaceutical ingredient development from years to months.
Lupin has agreed a “long-term strategic alliance” with CDMO PolyPeptide that the firm says will bolster its supply chain for peptide APIs.
Axplora made waves with a recent announcement that the API specialist’s total investments for 2025 would exceed €100m. Anant Barbadikar, co-president of the firm’s PharmaZell business unit, explains how the firm’s strategy is evolving and why he believes the future of pharma remains small-molecule.
Teva has ended exclusive talks to sell its active pharmaceutical ingredients arm after failing to reach terms that aligned with its strategic and shareholder interests, but plans to relaunch the process as shifting geopolitical and market conditions renew buyer interest.
Sandoz’s CEO used the firm’s latest results call to highlight “trade distortion” in the pencillins market as a result of US tariffs, urging European authorities to take action to reduce the region’s “geopolitical exposure” and safeguard the long-term sustainability of European-produced penicillins.
FDA rejects NPAs arguments for clarity on when it recognizes start of investigational new drug programs and what constitutes “substantial clinical investigations” for an IND. Clock starts after FDA met twice-extended deadline to provide answers to NPA’s questions in a 2023 petition.
Teva has indicated that it is closer than ever to an agreement to finally sell its TAPI active pharmaceutical ingredients business. However, a deal is not a certainty just yet, as “issues remain” around the divestment.